Nebenwirkungen · Ozurdex
OZURDEX 700 micrograms intravitreal implant in applicator · Abschnitt 4.8 · PDF-Seite 7
HOS-122537 · Präparat HOS-095531
In the 3 year DME clinical studies, at baseline, 87% of patients with a phakic study eye treated with OZURDEX had some degree of lens opacification/ early cataract. The incidence of all observed cataract types (i.e. cataract cortical, cataract diabetic, cataract nuclear, cataract subcapsular, cataract lenticular, cataract) was 68% in OZURDEX treated patients with a phakic study eye across the 3 year studies. 59% of patients with a phakic study eye required cataract surgery by the 3 year final visit, with the majority performed in the 2nd and 3rd years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-29T16:00:00Z · SHA-256 53363d650dca503ce72c050813175e5baa834767d0b4c57e771b47a209bcad35 · Passage bdaf1c6bff02dcecb0f0e95dd76e319457c83fd633241aee9f6080b5f122f647 · Zeichen 4370–4928 im Abschnitt